Emerald Mutual Fund Advisers Trust Sells 5,011 Shares of Insmed, Inc. $INSM

Emerald Mutual Fund Advisers Trust decreased its position in shares of Insmed, Inc. (NASDAQ:INSM) by 37.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 8,230 shares of the biopharmaceutical company’s stock after selling 5,011 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Insmed were worth $1,346,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 69 shares during the period. ORG Partners LLC boosted its position in Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares during the last quarter. Private Advisor Group LLC grew its position in Insmed by 1.8% during the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock valued at $777,000 after buying an additional 82 shares during the period. Finally, Allworth Financial LP grew its position in shares of Insmed by 20.5% during the 4th quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 108 shares during the period.

Insmed Price Performance

Shares of Insmed stock opened at $109.14 on Tuesday. The stock’s 50-day simple moving average is $106.67 and its 200-day simple moving average is $137.53. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The company has a market capitalization of $23.66 billion, a price-to-earnings ratio of -18.98 and a beta of 0.78. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. During the same quarter in the prior year, the company posted ($1.42) earnings per share. The business’s quarterly revenue was up 229.7% compared to the same quarter last year. As a group, analysts expect that Insmed, Inc. will post -2.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on INSM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Morgan Stanley raised shares of Insmed from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $166.00 to $212.00 in a report on Monday, March 30th. Wells Fargo & Company decreased their target price on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Leerink Partners lifted their price target on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Insmed in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Insiders Place Their Bets

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the transaction, the chief financial officer directly owned 69,082 shares in the company, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $108.47, for a total transaction of $666,982.03. Following the sale, the insider directly owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. This trade represents a 12.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,289 shares of company stock valued at $7,334,073 in the last 90 days. 2.10% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.